Angiogenex is aligned with some of the leading names in cancer research. Click on an image to be redirected to their website.
Since the discovery of the role of the ID genes in neo-vascularization and tumor proliferation in Dr. Benezra's lab, MSKCC has continued to provide invaluable support for the effort. It has helped to validate the ID platform with research into the basic biology of the mechanism of action and the medicinal chemistry of the target molecules and potential inhibitors. This work has identified numerous cancer types including breast, lung, prostate and brain where ID inhibition could be a game changing approach. Created on the heels of Benezra's discovery of this new target, AngioGenex's mission has been to commercialize its potential by developing small molecules that block the mechanism and prevent tumor formation. Over the years AngioGenex's symbiotic relationship with Memorial Sloan Kettering has taken the form of Industrial Research, Contract Research, Exclusive Licensing, Material Transfer Agreements, exclusive licenses and MSKCC's status as a holder of significant equity in the Company.
Dr. Benezra's Lab has been a recipient of significant annual support from the Estee Lauder Breast Cancer Research Foundation that has contributed to the validation of his initial findings of the requirement of ID protein activity in the establishment and metastasis of breast cancer. Under the leadership of Dr. Larry Norton (also a Member of the AngioGenex Scientific Advisory Board and our own Chief Medical Officer), and with the current threat to NIH and other sources of funding, the BCRF' continues to provide significant fressources for basic research in Dr. Benezra's Lab at Memorial Sloan Kettering.
Dr. Peter Campochiaro, the George S. and Dolores D. Eccles Professor of Ophthalmology at the Johns Hopkins University School of Medicine, a faculty member at the Wilmer Eye Institute at Johns Hopkins, and the pre-eminent researcher in the field of Age Related Macular Degeneration (ARMD) is a proud partner of AngioGenex. Under a Grant to the Institute, AngioGenex is engaged in a scientific collaboration with Dr. Campochiaro’s lab that has already confirmed in vivo the activity of AngioGenex’s lead drug AGx51, where it out-performed the ARMD standard of care Regenron’s highly profitable drug Eylea. The current work will select the most active of the Company’s drugs, and the optimum dose range, as its pre-clinical ocular lead drug candidate for further pre-clinical testing and IND submission.
Since its inception, AngioGenex has applied for and received funding from the United States’s National Institutes of Health( NIH) and the National Cancer Institute (NCI). AngioGenex received a Small Business Industrial Research (SBIR) Grant to study its bio-technology and drugs. Specifically ,the SBIR Grant funded experiments that established the enhanced anti-cancer effect of AGx51 administered in combination with Taxol (see graph here for more details). The studies at the NCI established that AGx51 crosses the blood brain barrier or interface and could potentially be used to treat brain cancers after oral or systemic administration.